A new £3 million Dementia Consortium has been launched to expedite development of new drugs for dementia. The Dementia Consortium unites the charity Alzheimer’s Research UK with life science technology transfer experts MRC Technology and pharmaceutical companies Eisai and Lilly.
Actavis plc announced that it its subsidiary, Warner Chilcott Co. LLC, has entered into an...
GlaxoSmithKline (GSK) today announced a series of investments totaling approximately £200...
Sanofi and Genzyme announced that the FDA has granted a six-month Priority Review designation to...
Teva Pharmaceutical Industries Ltd. said Tuesday that its 2014 earnings and revenue may be hurt if government officials approve generic versions of its multiple sclerosis treatment Copaxone.
This year's Challenge calls on non-profit patient, provider and professional associations to partner with other associations and/or academic institutions to propose new approaches which translate patient insights into improvements in the drug development process. Learn more...
Novartis Pharmaceuticals UK Limited has announced the launch of the UK’s largest clinical trial to investigate a potential new biologic treatment for adults with moderate-severe psoriasis.
The European Commission has fined pharmaceuticals giants Johnson & Johnson and Novartis a combined $22 million for colluding to delay the entrance of a cheap generic form of a pain killer to the Dutch market.
New data analyses show that Boehringer-Ingelheim's Pradaxa was consistent in a wide range of patients with acute deep vein thrombosis, a blood clot in the leg veins, or pulmonary embolism, a blood clot in the lung, regardless of age, renal function, simultaneous use of NSAIDs or low-dose ASA or the presence of cancer.
Takeda today announced that a joint panel of members from the Gastrointestinal Drugs and Drug Safety and Risk Management Advisory Committees of the FDA voted to recommend approval of vedolizumab for the treatment of adults with moderately to severely active ulcerative colitis (UC) and Crohn's disease (CD).
Daiichi Sankyo Co. Ltd. announced results of the Phase 3 Hokusai-VTE study, where patients with either a history of cancer or with active cancer treated with the once-daily factor Xa-inhibitor edoxaban had a lower incidence of recurrent symptomatic venous thromboembolism (VTE) compared to warfarin.
Adding bortezomib to standard preventive therapy for graft-versus-host-disease results in improved outcomes for patients receiving stem cell transplants from mismatched and unrelated donors, according to new research.
Myriad Genetics Inc. today announced that Janssen Research & Development LLC will use Myriad's BRACAnalysis test in connection with its Phase 3 clinical trial of Yondelis (trabectedin) in the treatment of advanced-relapsed epithelial ovarian, primary peritoneal or fallopian tube cancers. Learn more...
Shares of Acura Pharmaceuticals Inc. rose Monday after the company said it met with federal regulators to discuss a new version of the painkiller hydrocodone that uses the company's abuse-resistant technology.
Janssen, the pharmaceutical companies of Johnson & Johnson, today announced a first-of-its-kind pediatric HIV treatment donation program to improve access to the company's approved HIV medicines for children and adolescents failing HIV treatment in sub-Saharan Africa.
Merck Serono announced that The Lancet Oncology has published results from the Phase 3 trial of its investigational MUC1 antigen specific cancer immunotherapy tecemotide in patients with unresectable, locally advanced Stage III non-small cell lung cancer, known as the START trial.
Princeton University has announced that a vaccination program with Novartis meningococcal serogroup B (MenB) vaccine, Bexsero (Meningococcal Group B Vaccine), began today following a campus outbreak that has affected at least eight students.
Millennium: The Takeda Oncology Co., together with Takeda Pharmaceutical Co. Ltd., announced results from a retrospective, subgroup analysis of the Phase 3 VISTA study that showed a higher cumulative dose of Velcade suggests improved overall survival in previously untreated patients with multiple myeloma.
U.S. health officials have approved a highly anticipated hepatitis C drug from Gilead Sciences Inc. that is expected to offer a faster, more palatable cure to millions of people infected with the liver-destroying virus.
Medivation's Xtandi (enzalutamide) has been approved since June 2013 in the European Union (EU) for men with metastatic prostate cancer, and, in an early benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) found that the drug might offer an added benefit over the appropriate comparator therapy. So what are these potential added benefits? Find out...
Shire plc announced top-line results from OPUS-2, a Phase 3 efficacy and safety study of 5% lifitegrast ophthalmic solution. Lifitegrast met the prespecified co-primary endpoint for the patient-reported symptom of eye dryness, but did not meet co-primary endpoint for the sign of inferior corneal staining score.
AstraZeneca today announced that the European Commission (EC) has granted Marketing Authorization to Fluenz Tetra. This makes Fluenz Tetra the first and only intra-nasal four-strain influenza vaccine available in Europe.
GSK announced that the European Commission has granted marketing authorization for an additional indication for Synflorix for the immunization against pneumonia caused by Streptococcus pneumonia in children from six weeks up to five years of age.
GlaxoSmithKline (GSK) announced the formation of the Oncology Clinical and Translational Consortium (OCTC), a collaborative scientific research network comprised of six internationally renowned comprehensive cancer centers.
Pfizer Inc. announced an update of its clinical trial data access policy that will simplify and broaden access to information gathered in Pfizer-sponsored clinical trials. How does the updated policy build upon the company’s established methods of clinical trial information sharing? Find out...
Biogen Idec and Swedish Orphan Biovitrum AB (Sobi) announced the publication of detailed results from the pivotal Phase 3 study of Alprolix in The New England Journal of Medicine. So did the results show improved care for hemophilia patients?
Hoffmann-La Roche Ltd. (Roche), in consultation with Health Canada, announced important new safety information regarding the use of Xeloda. Severe skin reactions have been reported in patients taking Xeloda.
Mylan Inc. announced that it has completed the acquisition of India's Agila injectables businesses from Strides Arcolab Ltd. for up to $1.75 billion, which includes $250 million in contingent consideration.
Marinomed Biotechnologie GmbH announced that new clinical data confirmed the effectiveness of a Carragelose-based nasal spray in the therapy of common cold. The indicates regular use of the product can significantly reduces the duration of common cold symptoms.
- Page 1